January, 23 2012, 09:54am EDT
Largest Corporate Dairy, Biotech Firm and USDA Accused of Conspiring to Corrupt Rulemaking and Pollute Organics
Watchdog Requests Federal Investigation, Files Ethics Charges
WASHINGTON
The Cornucopia Institute, an organic industry research and watchdog organization, announced it has formally requested the USDA's Office of Inspector General (OIG) to investigate corruption at its National Organic Program resulting in the use of illegal synthetics in organic food and then allowing powerful corporations to "game the system" for approval "after the fact."
The controversy surrounds products developed by Martek Biosciences Corporation. Martek, part of a $12 billion Dutch-based conglomerate, recently petitioned for approval of its genetically modified soil fungus and algae as nutritional supplements in organic food.
Martek's formulated oils are processed with synthetic petrochemical solvents in a blend containing a myriad of other synthetic chemicals. Supplements derived from these oils, commonly marketed as DHA and ARA, are being added to milk, infant formula and other organic foods by such companies as Dean Foods (Horizon), Abbott Laboratories (Similac) and Nurture, Inc. (Happy Baby).
"This is a long-standing controversy that the USDA seems to think is just going to go away," said Mark A. Kastel, Codirector of the Wisconsin-based Cornucopia Institute.
After a formal legal complaint by Cornucopia, and an investigative story by the Washington Post, the USDA announced in April 2010 that it had "inappropriately" allowed Martek oils to be included in organic foods.
The scandal contributed to the removal of the previous director of the National Organic Program (NOP), who overruled her staff's decision finding Martek supplements were illegal in organics--after she met with a prominent Washington lobbyist, William J. Friedman.
The former NOP director's decision was reversed in April 2010. But instead of immediately ordering the removal of these unapproved synthetics from organic food, the Obama/Vilsack administration at the USDA delayed enforcement by 18 months in an apparent effort to permit corporate lobbyists to properly petition for review and possibly legal inclusion in organic food.
"It's unacceptable that these materials are still in organic food and that corporations think they can manipulate the system and get away with it," said Kastel. "It's even worse because, according to our research and reports at the FDA, some babies have become ill after consuming Martek supplements in infant formula."
In December, the National Organic Standards Board (NOSB), the expert panel set up by Congress to advise the USDA Secretary on organic matters, narrowly approved the Martek petitions for their patented versions of DHA and ARA. "All hell broke loose at the meeting in Savannah as the controversy grew extremely heated," Kastel noted.
In their complaint to the OIG, Cornucopia alleges that Martek misrepresented their novel, synthetic product and manipulated the vote by the NOSB.
"Martek oils, marketed under the Life'sDHA(tm) brand and included in organic infant formula, milk and baby food, are processed with petrochemical solvents like hexane or isopropyl alcohol, both of which are explicitly banned in organic production," stated Charlotte Vallaeys, Director of Farm and Food Policy at Cornucopia.
Although Martek told the board that they would discontinue the use of the controversial neurotoxic solvent n-hexane for DHA/ARA processing, they did not disclose what other synthetic solvents would be substituted. Federal organic standards prohibit the use of all synthetic/petrochemical solvents, including isopropyl alcohol, which is currently used to extract DHA algal oil for use in products such as Horizon milk.
Martek again brought in William "Jay" Friedman, with the powerful Washington law firm of Covington and Burling, to lead their approval process. Friedman appeared to deliberately mislead NOSB members into believing that the powdered form of Martek's DHA oil was not covered in the petition. This particular product formulation uses microencapsulation (banned in organics) and includes a number of additional synthetic materials that have never been reviewed or approved for use in organics.
When asked by NOSB Board chairperson, Tracy Miedema, "Are we approving dried powder or just oil?" Friedman stated on the record, "I can answer that. That's not the petitioned material."
Friedman's statement was inconsistent with Martek's formal petition to the NOSB, which states that "the petitioned material is unchanged from that which was authorized previously," referring to the USDA's earlier corrupted authorization of all Martek's products, including the powdered form.
"Mr. Friedman's statement thus appears patently false in an apparent attempt to intentionally mislead the NOSB. This apparent subterfuge led, in turn, to the NOSB's failure to review other aspects of these materials which would have disqualified them, under law, for inclusion in organic food," Cornucopia's Kastel said.
In addition to the letter to the OIG, Cornucopia has requested the D.C. Bar conduct a formal ethics investigation of Mr. Friedman's conduct.
"The dog and pony show put on by Martek and their largest customer, Dean Foods, was without precedent in the organic industry," said Alexis Baden-Mayer, Political Director of the Organic Consumers Association, who was present in Savannah.
The only scientists who testified at the meeting on the DHA issue were all on Martek's payroll, and focused on research showing benefits of consuming naturally occurring omega-3 fatty acids (such as those found in fish and breast milk), while ignoring the preponderance of published peer-reviewed research that shows that these health benefits are not gained from consuming Martek's novel, manufactured DHA additive.
The written statements of leading scientists in this field, who did not attend the meeting but whose findings were presented to the Board members, including assertions that this field of research is "driven to a large extent by enthusiasm and vested interest," were overpowered by the handful of corporate-sponsored scientists with a blatant financial interest in the outcome of the vote.
Dean Foods, Martek's largest customer, brought in a well-known web-pediatrician, Dr. Alan Greene, who has acted as a public relations agent endorsing Horizon brand organic milk with the added Martek DHA oils.
Although Dr. Greene represented himself as a "consultant," simply answering questions for Dean Foods, and stated he had previously worked for two other organic companies, but failed to disclose his multiple conflicts of interest in commenting on the benefits of Martek's manufactured DHA supplements.
Greene has also accepted compensation from Mead Johnson, the largest conventional infant formula manufacturer, to promote Martek's DHA oil in their products, and even has his own product line of nutritional supplements that include Martek DHA, marketed by Twinlabs with his name and photograph on the product package.
"It is unconscionable that a physician, who accepted money from a big drug company to promote synthetic DHA--which many believes promotes the use of baby formula at the expense of the nutrients in breast feeding--failed to disclose such a gross conflict of interest when he testified before the governmental body on certified 'organic' standards," said Lisa Graves, Executive Director of the Center for Media and Democracy/PRWatch, which helps expose corporate PR tactics.
Greene's role on behalf of Dean Foods and Martek was to directly dispute the preponderance of scientific literature, including two meta-analyses, that discredits Martek's claims that their supplements promote cognitive development in infants and children.
Cornucopia's complaint to the OIG also included evidence documenting that three corporate-backed members of the NOSB, who voted in favor of this petition, had undeclared conflicts of interest.
Two of the board members work for Earthbound Farms, a giant produce distributor that also compensated Dr. Greene during 2011. A third member of the NOSB board works for General Mills which partnered with Martek, starting in 2009, on the technology to microencapsulate their DHA and ARA oils.
Cornucopia said that these board members should have considered recusing themselves from voting on this issue because of the apparent conflicts of interest. One of the members was the prime champion of the Martek petition during board deliberations.
Adding fuel to the controversy, the Federal Trade Commission (FTC) just announced the end of its investigation into Dean Foods' advertising campaign for Horizon DHA supplemented milk, forcing the dairy giant to alter claims in its advertising concerning "brain development or function, cognitive development or function, intelligence, learning abilities in children over the age of two." This action resulted from a complaint filed by The Cornucopia Institute based on its research of the fraudulent and misleading health claims.
"While they did not fine Dean, or its WhiteWave division, for its misrepresentations in Horizon marketing, we are pleased that the FTC has taken this action to protect children and prevent the defrauding of their parents," said Vallaeys.
Although the FDA has dismissed complaints about the safety of Martek products in infant formula, reports persist from parents and healthcare providers of infants who experience serious gastrointestinal symptoms from consuming Martek's DHA and ARA oils in infant formula, raising serious public health questions about the marketing of these products.
The Cornucopia Institute has sent a formal briefing paper on these matters to all members of the National Organic Standards Board.
Cornucopia contends that the board did not fulfill its legal responsibilities of due diligence, and instead solely accepted unsubstantiated statements by Martek that their products were not genetically engineered and were not "synthetic."
"We are asking the NOSB to reopen their deliberations and consider rescinding their approval of Martek nutritional oils," Kastel added. "If the board fails to act now, protecting the integrity of organics, it risks changing the working definition of the organic seal and degrading its value in the eyes of consumers."
The Cornucopia Institute, a Wisconsin-based nonprofit farm policy research group, is dedicated to the fight for economic justice for the family-scale farming community. Their Organic Integrity Project acts as a corporate and governmental watchdog assuring that no compromises to the credibility of organic farming methods and the food it produces are made in the pursuit of profit.
LATEST NEWS
Congressional Progressives to Fed: Cut Rates to 'End This Squeeze' on Workers
Lawmakers warned Federal Reserve Chair Jerome Powell that keeping interest rates high "needlessly worsens housing market imbalances" and "could threaten" workers' jobs and wages.
Mar 18, 2024
Progressive lawmakers in the House and Senate urged the Federal Reserve on Monday to begin slashing interest rates in the near future, warning that the increasingly tight monetary conditions the central bank has imposed over the past two years risk imperiling strong post-pandemic job and
wage growth.
In a
letter to Fed Chair Jerome Powell, Sens. Bernie Sanders (I-Vt.) and Elizabeth Warren (D-Mass.) joined 19 House Democrats in calling for a "prompt timeline for future rate reductions," noting that the central bank has hiked rates 11 times since March 2022 and that inflation has nearly fallen "into line with the Federal Reserve's target."
"Today's excessively contractionary monetary policy needlessly worsens housing market imbalances and the unaffordability of home ownership, creates risks for banking stability, and could threaten the achievements of strong employment and wage growth and its attendant reductions in economic and racial inequalities," reads the letter, which was sent a day ahead of the Federal Open Market Committee's (FOMC) March 19-20 meeting.
If the Fed waits too long to begin cutting rates, the lawmakers cautioned, overly restrictive monetary policy could "reduce employment and real wage growth."
"We worry that higher unemployment and a harmful economic slowdown could result from a lagged effect of the prior 11 interest rate hikes since March 2022," the lawmakers added. "We believe it is critical for the FOMC to present the public with a clear and rapid timetable for reducing interest rates, ideally beginning at the May FOMC meeting in order to ensure a strong labor market and full employment for working Americans."
The Federal Reserve has raised interest rates 11 times in the last 2 years, keeping working people from being able to get a raise, a mortgage, or car.
Today, @SenSanders, @SenWarren, and House progressives call on the Fed to finally lower interest rates.https://t.co/VvFNPwZ8lS
— Progressive Caucus (@USProgressives) March 18, 2024
Since the Fed started raising interest rates for the first time since 2018 just over two years ago, progressive lawmakers, advocates, and economists have been arguing that jacking up borrowing was not the solution to inflation fueled in large part by pandemic-related supply chain disruptions and corporate price gouging. According to one recent study by the Groundwork Collaborative, corporate profiteering drove more than half of inflation between April and September 2023.
Last month, following a strong jobs report, Groundwork's Bilal Baydoun called for rate cuts, arguing that "the data is very clear that we never had to sacrifice jobs for lower prices."
"High interest rates will only slow our clean energy transition and put families in more debt," said Baydoun. "Chair Powell must change his tune and cut rates in March."
But the Fed is not expected to announce rate cuts following the two-day FOMC meeting that begins on Tuesday. The Associated Pressreported Monday that "Powell and his fellow Fed officials are expected to play it safe when they meet his week, keeping their rate unchanged for a fifth straight time and signaling that they still need further evidence that inflation is returning sustainably to their 2% target."
The Consumer Price Index (CPI) report released last week showed that overall inflation was 3.2% year-over-year—a slight uptick from January's reading but far below the 9.1% peak in 2022.
Hiring, meanwhile, has remained strong even as Powell has explicitly targeted the jobs market and workers' wages. Employers added 275,000 jobs last month, according to the U.S. Labor Department, and unemployment stayed low at 3.9%.
Rep. Pramila Jayapal (D-Wash.), chair of the Congressional Progressive Caucus, said in a statement Monday that "the American economy recovered from Covid because congressional Democrats and President Biden partnered to invest in workers over corporations and created paths to economic security for people who had been locked out before."
"Unnecessarily high rates put all that at risk," Jayapal added. "They will only punish everyday Americans: exacerbating the housing crisis, hindering the deployment of clean energy, and throwing the future of the Biden recovery into uncertainty, while threatening the wages and jobs that our communities depend on. It's past time for the Fed to end this squeeze on working- and middle-class families."
Keep ReadingShow Less
Greenpeace Says Ban Deep-Sea Mining, Not Our Right to Protest Against It
"How can Greenpeace's activists paddling on kayaks be a threat to the environment, but the plundering of the oceans be a solution to the climate catastrophe?"
Mar 18, 2024
As the International Seabed Authority kicked off its annual summit in Jamaica on Monday to discuss rules for extracting minerals from the ocean floor, Greenpeace—which could be expelled from the United Nations body over a demonstration targeting a mining company—is urging the ISA to "stop deep-sea mining, not protests."
Representatives of 167 nations are gathering in Kingston to draft the regulatory framework for deep-sea mining, which ISA member states agreed to work out by July 2025. Although there are no current commercial deep seabed mining operations, the ISA has issued exploration licenses to state-owned companies and agencies in China, France, Germany, India, Japan, Russia, and South Korea, and to private corporations including U.K. Seabed Resources, a subsidiary of U.S. military-industrial complex giant Lockheed Martin.
The Metals Company, a Canadian startup looking to make a big splash in deep-sea mining, has been targeted by Greenpeace "kayaktivists," who last November boarded a ship belonging to subsidiary Nauru Ocean Resources Inc. in the Pacific Ocean and occupied the vessel's stern crane to draw attention to the potential harm that mineral extraction would cause to one of the world's last untouched ecosystems.
That peaceful protest could cost Greenpeace its ISA observer status, as members will consider whether to punish the environmental group during this week's conference. ISA Secretary-General Michael Lodge claimed that Greenpeace's kayak protest posed a "serious threat" to company personnel and "the marine environment."
However, last November a Dutch court rejected The Metals Company's request for an injunction against the protesters, finding it "understandable" that Greenpeace took direct action in the face of "possibly very serious consequences" of the company's mining plans.
Greenpeace plans to hold a side event at the ISA conference on Monday focusing on the right to protest.
"If Michael Lodge had put as much effort into properly scrutinizing deep-sea mining companies and ensuring transparent negotiations as he has chasing dissent, a pristine ecosystem would have a fair chance to remain undisturbed," said Greenpeace International Deep-Sea Mining campaign lead Louisa Casson. "How can Greenpeace's activists paddling on kayaks be a threat to the environment, but the plundering of the oceans be a solution to the climate catastrophe?"
This year's ISA conference comes as two dozen nations are calling for a moratorium on deep-sea mining and campaigners are urging the United States to ratify the U.N. Convention on the Law of the Sea, under which the ISA was established.
"Over the past year, it's been outstanding to see the growing call for a moratorium from countries in the Pacific, Europe, and Latin America," said Casson. "Responsible nations at the ISA are listening to the mounting science that shows deep-sea mining would cause irreversible damage to the oceans... The momentum is on the side of a moratorium."
There is also pushback. Last week, more than 350 former military and political leaders in the United States including former Secretary of State Hillary Clinton published a letter urging the U.S. Senate to sign and ratify the Law of the Sea in a bid to boost deep-sea mining amid rising international competition for minerals.
"Almost everyone agrees that the United States should ratify the Law of the Sea—it's a no-brainer and has been since the treaty was adopted over 40 years ago. This might be the only thing that Greenpeace and Big Oil agree with each other on," said Arlo Hemphill, who heads the Oceans Are Life campaign at Greenpeace USA.
"Now, deep-sea mining corporation The Metals Company has jumped on the bandwagon, hoping it will increase their chances of making it big after several costly failed ventures," Hemphill added. "With two dozen countries already on the record opposing the launch of deep-sea mining any time soon, there is little possibility it will be permitted."
However, earlier this year Norway became the first country to green-light deep-sea mining, a decision one environmental campaigner warned will have "severe impacts on ocean wildlife."
Keep ReadingShow Less
'Positive Step,' Says Sanders After AstraZeneca Agrees to Cap Inhalers at $35
"Americans who have asthma and COPD should not be forced to pay, in many cases, 10 to 70 times more for the same exact inhalers as patients in Europe and other parts of the world."
Mar 18, 2024
AstraZeneca announced Monday that it will cap out-of-pocket costs at $35 per month for U.S. inhaled respiratory medicines—becoming the second pharmaceutical giant to make that move since U.S. Sen. Bernie Sanders launched a probe in January.
The policy change—which will benefit patients with asthma and chronic obstructive pulmonary disease (COPD), including those who are uninsured and underinsured—is set to start in June, like the Boehringer Ingelheim decision announced earlier this month.
While welcoming the development, Sanders (I-Vt.) noted that it comes after the Senate Committee on Health, Education, Labor, and Pensions (HELP) that he chairs began investigating "the outrageously high cost of inhalers that 25 million Americans with asthma and 16 million Americans with COPD rely on to breathe."
"If AstraZeneca and Boehringer Ingelheim can cap the cost of inhalers at $35 in the United States, these other companies can do the same."
"In my view, Americans who have asthma and COPD should not be forced to pay, in many cases, 10 to 70 times more for the same exact inhalers as patients in Europe and other parts of the world," declared Sanders. "Since we launched that investigation, I have had conversations with all of the CEOs of the major manufacturers of these products."
The senator said that he is "very pleased" with AstraZeneca's announcement, adding that "this is a very positive step which will help save Americans thousands of dollars a year on the inhalers they need to breathe."
The panel's probe—supported by Sens. Tammy Baldwin (D-Wis.), Ben Ray Luján (D-N.M.), and Ed Markey (D-Mass.)—also targets GlaxoSmithKline (GSK) and Teva. Sanders called on the pair to "take similar action," arguing that "if AstraZeneca and Boehringer Ingelheim can cap the cost of inhalers at $35 in the United States, these other companies can do the same."
Sanders pledged that his committee "will continue to do everything we can do to make sure that Americans no longer pay, by far, the highest prices in the world for prescription drugs."
In AstraZeneca's announcement, CEO Pascal Soriot called for federal action, saying that "we remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone. It is critical that Congress bring together key stakeholders to help reform the healthcare system so patients can afford the medicines they need, not just today, but for the future."
AstraZeneca highlighted that the cap will apply to medicines including Airsupra, Bevespi Aerosphere, Breztri Aerosphere, and Symbicort—which cost up to $645—and that the company "substantially reduced the list price" of Symbicort at the beginning of the year.
The Federal Trade Commission (FTC) in November disputed more than 100 patents held by pharmaceutical companies that make asthma inhalers, EpiPens, and other products listed in a Food and Drug Administration database, including Symbicort.
Acknowledging AstraZeneca's cap decision, FTC Chair Lina Khan said on social media Monday, "I urge the other firms whose patents FTC challenged—including GSK and Teva—to withdraw their improperly listed patents and drop costs for Americans."
Keep ReadingShow Less
Most Popular